CliffBio
small molecule

ELEPSIA XR

LEVETIRACETAM

Loss of exclusivityOctober 2027latest FDA-listed patent expiry
CompanyTRIPOINT THERAPEUTICS

Drug detail

Brand nameELEPSIA XR
Active ingredientLEVETIRACETAM
Strength1.5GM
Dosage formTABLET, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalDecember 2018
Marketing statusDISCN

Listed patents

PatentExpiresType
8431156October 2027product
8470367October 2027product
8163306September 2027product
8535717February 2026product
8425938February 2026product

More from TRIPOINT THERAPEUTICS

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ELEPSIA XR patent cliff — loss of exclusivity October 2027 | CliffBio